盐皮质激素受体拮抗剂与恩格列净在射血分数保留的心力衰竭患者中的研究
本研究基于EMPEROR-Preserved试验,分析基线使用或不使用盐皮质激素受体拮抗剂(MRA)对恩格列净疗效的影响。共纳入5988例患者,其中2244例(37.5%)使用MRA。结果显示,恩格列净降低主要结局的获益在MRA使用与否间无显著差异,但减少心衰住院的疗效在未使用MRA者中更明显;恩格列净降低高钾血症风险不受MRA使用影响。
要点
- 恩格列净降低主要结局的获益在MRA使用与否间无显著差异。
- 恩格列净减少心衰住院的疗效在未使用MRA者中更明显。
- 恩格列净降低高钾血症风险,与MRA使用无显著交互作用。
核心结论
- 恩格列净降低主要结局的获益在MRA使用与否间无显著差异。
- 恩格列净减少首次和复发性心衰住院的疗效在未使用MRA者中更明显。
- 恩格列净降低高钾血症风险,与MRA使用无显著交互作用。
研究设计与样本
- 本研究为EMPEROR-Preserved试验的事后分析,比较恩格列净与安慰剂在基线使用或不使用MRA患者中的疗效。
- 共纳入5988例患者,其中2244例(37.5%)基线使用MRA。
主要发现
- MRA使用者的事件率高于未使用者(安慰剂组主要结局:每100人年9.4 vs 8.2次事件)。
- 恩格列净降低主要结局的HR在MRA未使用者为0.73(95%CI:0.62-0.87),在MRA使用者为0.87(95%CI:0.71-1.06),交互P=0.22。
- 恩格列净减少首次和复发性心衰住院的HR在MRA未使用者为0.60(95%CI:0.47-0.77),在MRA使用者为0.90(95%CI:0.68-1.19),交互P=0.038。
- MRA使用者的高钾血症事件约为未使用者的两倍。
- 恩格列净降低高钾血症或启动钾结合剂的风险,在MRA未使用者HR为0.90(95%CI:0.69-1.19),在MRA使用者HR为0.74(95%CI:0.56-0.96),交互P=0.29。
临床怎么用
- 对于射血分数保留的心衰患者,无论是否使用MRA,恩格列净均可降低主要结局风险。
- 在未使用MRA的患者中,恩格列净减少心衰住院的获益可能更明显。
- 恩格列净可降低高钾血症风险,且该作用不受MRA使用影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) may be beneficial in reducing heart failure (HF) hospitalizations in patients with HF with preserved ejection fraction. The effect of sodium-glucose cotransporter 2 inhibitors in patients with HF with preserved ejection fraction according to MRA background therapy has not been reported. OBJECTIVES: The aim of this study was to examine the effect of empagliflozin in MRA users and nonusers in the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) trial. METHODS: Survival analyses were conducted comparing the effects of empagliflozin vs placebo in MRA users and nonusers at baseline with treatment-by-MRA use interaction terms. RESULTS: A total of 5,988 patients were included, of whom 2,244 (37.5%) were using MRAs at baseline. MRA users had higher event rates than MRA nonusers (placebo group primary outcome 9.4 vs 8.2 events per 100 person-years). The benefit of empagliflozin to reduce the primary outcome was not significantly different between MRA nonusers and MRA users (HR: 0.73 [95% CI: 0.62-0.87] and HR: 0.87 [95% CI: 0.71-1.06]; interaction P = 0.22). The effect of empagliflozin to reduce first and recurrent HF hospitalizations was more pronounced in MRA nonusers than in MRA users (HR: 0.60 [95% CI: 0.47-0.77] and HR: 0.90 [95% CI: 0.68-1.19]; interaction P = 0.038). MRA users experienced almost twice as many hyperkalemia events as MRA nonusers, and empagliflozin reduced the risk for hyperkalemia or initiation of potassium binders regardless of MRA use (MRA nonusers: HR: 0.90 [95% CI: 0.69-1.19]; MRA users: HR: 0.74 [95% CI: 0.56-0.96]; interaction P = 0.29). CONCLUSIONS: The benefit of empagliflozin to reduce the primary outcome was not significantly different between MRA nonusers and MRA users. The effect of empagliflozin to reduce first and recurrent HF hospitalizations was more pronounced in MRA nonusers. Empagliflozin reduced hyperkalemia, with no significant treatment-by-MRA subgroup interaction. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction [EMPEROR-Preserved]; NCT03057951).
引用
- Ferreira, Butler, Zannad, et al. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2022. PMID: 35331406. doi:10.1016/j.jacc.2022.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。